ASCO

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).

Doxorubicin Hydrochloride, Lenalidomide, and Dexamethasone versus Bortezomib, Lenalidomide, and Dexamethasone Prior to Scheduled Stem-Cell Transplant in Newly Diagnosed Myeloma

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.

Lenalidomide Induction and Maintenance Therapy for Transplant-Eligible Myeloma Patients: Results of the Myeloma XI Study

The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma.

Impact of t(11;14) on Outcomes in African American and Non–African American Patients with NDMM: Connect MM Registry

Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation.

Pembrolizumab plus Lenalidomide and Low-Dose Dexamethasone for RRMM: Efficacy and Biomarker Analyses

Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM).

First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T-Cell Therapy for RRMM: Updated Results

Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM).

Pomalidomide + Low-Dose Dexamethasone after Lenalidomide-Based Second-Line Treatment in Patients with RRMM: Analysis of Progression-Free Survival by Level of Disease Control

Pomalidomide plus low-dose dexamethasone used as third-line therapy improves survival outcomes in patients with relapsed/refractory multiple myeloma (RRMM).

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide versus Placebo Maintenance After Stem-Cell Transplant for Patients with MM—OS and PFS Adjusted for Treatment Crossover

This phase 3 study compared lenalidomide maintenance versus placebo after stem-cell transplant in patients with newly diagnosed multiple myeloma, adjusting overall survival (OS) and progression-free survival (PFS) for treatment crossover.

Impact of Post-ASCT Maintenance Therapy on Outcomes in Patients with NDMM Using the Large, Prospective Community-Based Connect MM Registry

Insights from the Connect MM Registry show that lenalidomide maintenance therapy after autologous stem-cell transplant (ASCT) significantly improves progression-free survival and overall survival in patients with newly diagnosed multiple myeloma (NDMM).